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The major cell type supporting hepatitis C virus (HCV) infection is the hepatocyte; however, most
reports studying viral entry and replication utilize transformed hepatoma cell lines. We
demonstrate that HCV pseudoparticles (HCVpp) infect primary hepatocytes with comparable
rates to hepatoma cells, demonstrating the limited variability in donor hepatocytes to support HCV
receptor-glycoprotein-dependent entry. In contrast, we observed a 2-log range in viral replication
between the same donor hepatocytes. We noted that cell proliferation augments pseudoparticle
reporter activity and arresting hepatoma cells yields comparable levels of infection to hepatocytes.
This study demonstrates comparable rates of HCVpp entry into primary hepatocytes and
hepatoma cells, validating the use of transformed cells as a model system to study HCV entry.
Hepatitis C virus (HCV) affects 3% of the world’s popu-
lation and is a leading cause of chronic liver disease,
including fibrosis, cirrhosis and hepatocellular carcinoma
(Alter, 2007). The recent availability of direct-acting
antiviral agents has led to a significant improvement in
patient response rates (Scheel & Rice, 2013). However, the
cost of such treatments will be prohibitive in many parts
of the world, highlighting the need for immune-based
therapies for treating chronic hepatitis C and the develop-
ment of a preventive vaccine. HCV primarily infects
hepatocytes in the liver that are highly differentiated and
arrested in the G1 stage of the cell cycle (Farquhar &
McKeating, 2008; Taub, 2004). HCV initiates infection by
attaching to molecules or receptors at the cell surface and
current evidence supports an essential role for scavenger
receptor class B member I (SR-BI), tetraspanin CD81 and
tight-junction proteins claudin-1 and occludin in clathrin-
dependent particle endocytosis (Meredith et al., 2012; Ploss
& Evans, 2012). Additional accessory factors include low-
density lipoprotein receptor, epidermal growth factor
receptor, Niemann–Pick C1-like cholesterol receptor and
transferrin receptor (Baumert et al., 2014). To date, much of
our understanding of the viral life cycle derives from in vitro
studies with lentiviral pseudotypes transiently expressing HCV-
encoded glycoproteins (HCVpp) and infectious molecular
clones based on the JFH-1 strain of virus (HCVcc) infecting
transformed hepatoma cell lines (Farquhar &McKeating, 2008;
Wilson & Stamataki, 2012). In contrast, there are limited
reports of studies of HCV infection of primary hepatocytes
(PHHs) (Fofana et al., 2010; Podevin et al., 2010; Re´geard et al.,
2008) and importantly a lack of studies comparing their
permissivity to hepatoma cell lines.
First, we optimized the protocol for infecting PHHs with
HCVpp and HCVcc strain SA13/JFH. The former allows
the measurement of HCV glycoprotein-dependent entry.
Cells were infected 1, 2 or 4 days post-seeding with
luciferase-reporter pseudoparticles expressing HCV strain
H77 genotype 1a glycoproteins (HCVpp-H77) or control
vesicular stomatitis virus glycoprotein (VSV-Gpp) and
HCVcc in the presence or absence of monoclonal antibodies
targeting SR-BI or CD81. Infection was assessed 72 h
later by measuring luciferase or viral RNA, respectively
(Fig. 1a–c). HCVpp and HCVcc infected PHHs optimally at
2 days post-seeding, consistent with increased expression of
SR-BI and claudin-1 compared with day 1 cells (Fig. 1d–e).
However, it is noteworthy that CD81, SR-BI, claudin-1 and
occludin expression was optimal at 4 days post-plating,
suggesting that other factors independent of receptor
expression levels may regulate HCVpp entry. In contrast,
VSV-Gpp infected PHHs at all times post-seeding with
comparable luciferase activity (Fig. 1b). Anti-CD81 and
anti-SR-BI antibodies inhibited infection, confirming recep-
tor-dependent virus entry (Fig. 1a). We noted similar IC50
values for both anti-receptor antibodies to neutralize
HCVpp infection of PHHs and hepatoma cell lines (data
not shown). Having determined the optimal time to infect
PHHs after isolation from the liver, we compared the rate of
HCVpp and VSVpp infection of PHHs with the permissive
Huh-7.5 hepatoma cell line (Blight et al., 2003; Schwarz et al.,
2009). Virus was allowed to infect target cells for increasing
time periods up to 8 h, unbound virus was removed by
washing and luciferase activity was measured after 72 h
(Fig. 2). We observed comparable rates of HCVpp
[4535±220 and 4728±345 relative light units (RLU) h21]
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and VSV-Gpp (265 483±106 122 and 319 216±59 485
RLU h21) infection of PHHs and Huh-7.5 cells, respectively.
To assess the impact of donor variability on PHH
permissivity we compared cells isolated under GLP condi-
tions from five donors for their ability to support HCVpp
and HCVcc infection. All PHH preparations showed
comparable levels of HCVpp or VSV-G infection (Fig. 3a,
b). Similar data were obtained with HCVpp expressing a
variety of primary envelope glycoproteins (data not shown).
As controls, we included two commonly used hepatoma cell
lines, Huh-7.5 and Hep3B. We noted that the HCVpp-
encoded luciferase values for PHHs were approximately
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Fig. 1. Optimizing HCV infection of primary human hepatocytes. (a, b) Human hepatocytes were isolated according to
previously published protocols (Mitry, 2009) and maintained in Williams E medium supplemented with 10% FBS/5 mM
HEPES/insulin/dexamethasone. Hepatocytes were plated at 4104 cm”2 on collagen-coated plates and infected with HCVpp-
H77 or VSV-Gpp prepared as previously described (Hsu et al., 2003). Briefly 293T HEK cells were transfected with two
plasmids, one encoding the HIV provirus expressing luciferase and the other encoding HCV E1E2, VSV-G or a no-envelope
control. Supernatants were collected 48 h later, clarified, evaluated for HIV p24 content and used to infect target cells for 8 h
with an inoculum of 1 ng p24 per well at 1, 2 and 4 days post-seeding. Virus was removed by washing and cultures were
maintained at 37 6C for 72 h. At 72 h post-infection, cells were lysed and luciferase activity was measured using a luminometer
(Lumat LB 90507). Cells were incubated with anti-SR-BI or anti-CD81 (2s131) monoclonal antibodies at 5 mg ml”1 prior to
being inoculated with virus. Data are presented as relative light units (RLU) from which a no-envelope pseudotype control value
has been subtracted, and are representative of three experiments. Error bars indicate SD from the mean (n53); ***P,0.001; ns
denotes no statistical significance. (c) Cells were infected with HCVcc SA13/JFH as previously described (Jensen et al., 2008).
Virus-containing medium (1.8106 focus-forming units ml”1, approximate m.o.i. 0.01) was added to target cells for 8 h followed
by washing and change of medium. Infection was realized 72 h later by quantitative reverse transcriptase PCR detection of the
cellular viral RNA load using the Cells Direct kit (Life Technologies). Data are presented as HCV RNA copy number relative to
GAPDH and are representative of three independent experiments. ***P,0.001. (d) Confocal microscopy images of HCV
receptor molecules CD81 (2s131), claudin-1 and occludin (Life Technologies) in PHHs at 1, 2 or 4 days post-seeding on glass
coverslips. Cells were methanol-fixed and permeabilized with saponin (Sigma) followed by incubation with respective antibodies
(1 : 1000) for 1 h at room temperature in a PBS/BSA solution. Cells were washed three times before the addition of species-
appropriate Alexa-594-conjugated secondary antibodies (1 : 1000) for 1 h at room temperature. After a further wash the nuclei
were counterstained with DAPI and coverslips were mounted on glass slides using ProLong Gold antifade (Life Technologies).
Scale bars represent 20 mm. (e) Western blot detection of HCV receptor molecules including SR-BI in PHHs lysed at 1, 2 or
4 days post-seeding using a previously published protocol (Farquhar et al., 2012).
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Fig. 2. HCV entry kinetics. PHHs and Huh-7.5
cells were seeded at 4104 cm”2 on col-
lagen-coated plates and 2 days post-plating
were infected with HCVpp or VSV-Gpp. The
inoculum was removed at 2 h intervals up to
8 h and cultures were maintained for 72 h.
Data are presented as RLU from which a no-
envelope pseudotype control value has been
subtracted and are representative of three
independent experiments. Error bars indicate
SD from the mean (n53).
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Fig. 3. Cell proliferation augments pseudoparticle infection. PHHs, and Hep3B and Huh-7.5 cells were seeded at 4104 cm”2
on collagen-coated plates and 2 days post-plating were infected with HCVpp, VSV-Gpp (a, b) or HCV JFH-1 and SA13/JFH
(c) virus for 8 h as detailed in Fig. 1. Data are presented as RLU from which a no-envelope pseudotype control value has been
subtracted or as HCV RNA copy number relative to GAPDH and are representative of three independent experiments. (d)
Mitomycin C and c-irradiation block cell growth. Cells were treated with mitomycin C (10 mg ml”1, overnight) or c-irradiated
(32 mSv, 30 min) and proliferation was measured using an MTT assay (Promega) as per the manufacturer’s instructions; data
are presented as OD450. (e) Mitomycin C or c-irradiated cells were infected with HCVpp-H77 or VSV-Gpp. Cultures were
maintained at 37 6C for 72 h and luciferase activity was measured as described above. Data are presented relative to untreated
cells. (f) Control and mitomycin C-treated PHHs (donor 2) and Huh-7.5 cells were studied for their ability to support HCVpp-
H77 and VSV-G pseudoviruses expressing green fluorescent protein (GFP) reporter. GFP-expressing cells were detected 72 h
post-infection by flow cytometry. *P,0.05, **P,0.01, ***P,0.001 (t-test). Error bars indicate SD from the mean (n53).
HCV infection of primary human hepatocytes
http://vir.sgmjournals.org 1371
Downloaded from www.microbiologyresearch.org by
IP:  147.188.224.230
On: Wed, 09 Dec 2015 10:52:26
1-log lower compared with both hepatoma cells, suggesting
a lower frequency of infected cells in the PHH population.
The efficiency of the lentiviral promoter in the different cell
types could in part explain the different luciferase signals.
However, this is unlikely since the majority of donor
primary and hepatoma cells showed comparable VSV-Gpp
luciferase signals (Fig. 3b). In contrast to the pseudoparticle
infectivity data, we noted significant variability in the ability
of PHHs isolated from different donors to support
replication of HCV strains JFH-1 and SA13/JFH (Fig. 3c),
with levels of HCV RNA in PHHs at least 1-log lower than in
Huh-7.5 cells (Fig. 3c).
It is widely accepted that pseudoparticle reporter signals
reflect differences in glycoprotein-dependent entry, and
luciferase values are commonly used as a read-out in
antibody-based neutralization assays and for measuring
strain-dependent differences in virus entry. In the liver,
hepatocytes are largely quiescent and PHHs show minimal
proliferative capacity in vitro (Taub, 2004). In contrast,
hepatoma cells have a doubling time in the order of 18–
24 h (Sainz et al., 2012b). We hypothesized that prolifer-
ation of an infected cell may result in progeny daughter cells
bearing the reporter gene, resulting in an increased luciferase
signal that does not reflect the initial viral entry event per se.
To ascertain whether cell proliferation modulates HCVpp
and VSV-Gpp luciferase signals, PHHs and hepatoma
cells were arrested with mitomycin C or c-irradiation and
evaluated for pseudoparticle infection. Mitomycin C and
c-irradiation limited hepatoma growth and had no discern-
ible effect on PHH proliferation or viability (Fig. 3d). Both
treatments hadminimal effect on HCVpp or VSV-Gpp entry
into PHHs, consistent with the non-dividing nature of these
cells. In contrast, both treatments significantly reduced
HCVpp and VSV-Gpp infection of the hepatoma cell lines,
resulting in comparable luciferase values to PHHs (Fig. 3e).
To confirm our earlier model that Huh-7.5 proliferation
affects the number of pseudoparticle-infected cells, we
inoculated non-arrested and arrested PHHs and Huh-7.5
cells with HCVpp-H77 and VSV-Gpp bearing a GFP
reporter. Mitomycin C reduced the number of HCVpp
and VSV-Gpp-GFP-expressing Huh-7.5 cells but had no
impact on the number of infected PHHs (Fig. 3f).
Importantly, following mitomycin C treatment the numbers
of HCVpp-infected PHHs and Huh-7.5 cells were compar-
able (Fig. 3f).
In summary, we have shown that PHHs from multiple
donors support similar levels of HCVpp entry. In contrast,
the same donor hepatocytes showed significant differences
in their ability to support HCVcc replication, consistent
with recent reports showing donor-dependent differences
in innate signalling and type III interferon expression (Li &
Lemon, 2013; Marukian et al., 2011; Park et al., 2012). This
study raises an interesting question as to whether dif-
ferences in the frequency of infected hepatocytes and viral
RNA reported in chronically infected subjects (Liang et al.,
2009) are largely defined at the level of viral replication and
innate immune signalling rather than virus entry. We
report for the first time that hepatoma proliferation
increases HCVpp reporter signals, demonstrating that
luciferase values are not solely defined by the HCVpp
entry process. This is particularly pertinent when compar-
ing HCV entry into different cell types with varying growth
rates or when evaluating the effect of antibodies, growth
factors or kinase inhibitors with known effects on cell
proliferation (Lupberger et al., 2011; Marukian et al., 2008;
Sainz et al., 2012a). In summary, growth-arrested hepatoma
cell lines support comparable rates of HCVpp entry into
primary hepatocytes, validating their use as a surrogate
model system.
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